/RPHM

RPHM Stock - Reneo Pharmaceuticals, Inc.

Q: What is the analyst price target for RPHM?

Analyst price target information is not currently available for RPHM.

Q: What is RPHM's market cap?

Market capitalization information is not currently available for RPHM.

Healthcare|Biotechnology|NASDAQ

$18.20+952.02%

+$16.47 (+952.02%) • Oct 4

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

BUY

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $20.02

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for RPHM

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.22

52W High$82.90

52W Low$1.68

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	$-525,000	$-529,000	$-50,000	$-37,000
Gross Margin	N/A	N/A	N/A	N/A	N/A
Operating Income	$-54,386,000	$-83,053,000	$-53,848,000	$-39,818,000	$-19,552,000
Net Income	N/A	$-77,388,000	$-50,062,000	$-39,770,000	$-19,465,000
Net Margin	N/A	N/A	N/A	N/A	N/A
EPS	$0.00	$-2.30	$-2.04	$-2.19	$-0.80

Company Overview

Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

40%

Hold / Neutral

50%

Sell / Underperform

10%

Analyst Consensus🔴 Bearish

4 Bullish6 Neutral/Bearish

Price Targets

$15

Average Target

↓ 16.4% Downside

Now

Low

$15

Average

$36

High

Based on 7 analysts

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
December 15th 2023	Leerink Partners	Downgrade	Market Perform	-
December 15th 2023	Jefferies	Downgrade	Hold	-
December 15th 2023	H.C. Wainwright	Downgrade	Neutral	$1.5← $30
December 14th 2023	Ladenburg Thalmann	Downgrade	Neutral	-
December 14th 2023	BofA Securities	Downgrade	Underperform	$1.45← $23
December 14th 2023	William Blair	Downgrade	Market Perform	-
December 14th 2023	Robert W. Baird	Downgrade	Neutral	$3← $28
December 14th 2023	Piper Sandler	Downgrade	Neutral	$4← $25
November 15th 2023	William Blair	Initiation	Outperform	$35.55
August 28th 2023	H.C. Wainwright	Initiation	Buy	$30
July 3rd 2023	BofA Securities	Initiation	Buy	-
September 19th 2022	H.C. Wainwright	Resumed	Buy	$31

Earnings History & Surprises

RPHM

Beat Rate

60%

Last 15 quarters

Avg Surprise

-99.4%

EPS vs Estimate

Beats / Misses

9/6

Last 12 quarters

Latest EPS

$-1.09

Q4 2025

EPS Surprise History

Q1 24

-27.3%

$-0.70vs$-0.55

Q2 24

+32.4%

$-0.25vs$-0.37

Q3 24

+5.9%

$-0.16vs$-0.17

Q4 24

-714.3%

$-0.57vs$-0.07

Q1 25

No data

Q2 25

No data

Q3 25

No data

Q4 25

No data

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q4 2025	Nov 6, 2025	—	$-1.09	—	—
Q3 2025	Aug 11, 2025	—	$-1.14	—	—
Q2 2025	May 5, 2025	—	$-1.19	—	—
Q1 2025	Mar 26, 2025	—	$1.08	—	—
Q4 2024	Nov 11, 2024	$-0.07	$-0.57	-714.3%	✗ MISS
Q3 2024	Aug 13, 2024	$-0.17	$-0.16	+5.9%	✓ BEAT
Q2 2024	May 7, 2024	$-0.37	$-0.25	+32.4%	✓ BEAT
Q1 2024	Mar 28, 2024	$-0.55	$-0.70	-27.3%	✗ MISS
Q4 2023	Nov 13, 2023	$-0.60	$-0.57	+5.0%	✓ BEAT
Q3 2023	Aug 10, 2023	$-0.55	$-0.65	-18.2%	✗ MISS
Q2 2023	May 11, 2023	$-0.63	$-0.60	+4.8%	✓ BEAT
Q1 2023	Mar 27, 2023	$-0.62	$-0.56	+9.7%	✓ BEAT
Q4 2022	Nov 8, 2022	$-0.58	$-0.53	+8.6%	✓ BEAT
Q3 2022	Aug 9, 2022	$-0.60	$-0.50	+16.7%	✓ BEAT
Q2 2022	May 10, 2022	$-0.54	$-0.53	+1.9%	✓ BEAT
Q1 2022	Mar 23, 2022	$-0.59	$-0.43	+27.1%	✓ BEAT
Q4 2021	Nov 11, 2021	$-0.47	$-0.52	-10.6%	✗ MISS
Q3 2021	Aug 11, 2021	$-0.37	$-0.43	-16.2%	✗ MISS
Q2 2021	May 20, 2021	$-0.38	$-3.48	-815.8%	✗ MISS
Q1 2021	Mar 19, 2021	—	$-0.65	—	—

Frequently Asked Questions about RPHM

What is RPHM's current stock price?

Reneo Pharmaceuticals, Inc. (RPHM) is currently trading at $18.20 per share. The stock has moved +952.02% today.

What is the analyst price target for RPHM?

No analyst price targets are currently available for this stock.

What sector is Reneo Pharmaceuticals, Inc. in?

Reneo Pharmaceuticals, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is RPHM's market cap?

Reneo Pharmaceuticals, Inc. has a market capitalization of $0.06 billion, making it a small-cap company.

Does RPHM pay dividends?

No, Reneo Pharmaceuticals, Inc. does not currently pay a dividend to shareholders.